4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole → 2-(1H-indazol-4-yl)-6-((1-methylpiperidin-4-ylidene)methyl)-4-morpholinothieno[3,2-d]pyrimidine

Participants

Role	Name	HCID	Charge
Reactant	4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole	HCID 45480186	—
Reactant	2-Chloro-6-(1-methyl-piperidin-4-ylidenemethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine	HCID 86618399	—
Product	2-(1H-indazol-4-yl)-6-((1-methylpiperidin-4-ylidene)methyl)-4-morpholinothieno[3,2-d]pyrimidine	HCID 59592948	—

Reaction Steps

2-Chloro-6-(1-methyl-piperidin-4-ylidenemethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine was reacted with 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole in general procedure A. Purification on silica yielded 181. NMR: (CDCl3) 2.37 (3H, s); 2.55 (6H, m); 2.82 (2H, t, J=5.5 Hz); 3.93 (4H, t, J=4.8 Hz); 4.10 (4H, t, J=4.8 Hz); 6.44 (1H, s); 7.33 (1H, s); 7.51 (1H, s); 7.60 (1H, d, J=8.2 Hz); 8.28 (1H, d, J=7.1 Hz); 9.03 (1H, s); 10.25 (br s). M+H (447)

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US07846929B2
Source dataset	uspto-grants-2010_12
ORD ID	ord-ef9e20565e814d3cb2d1f846282eea90
Source note	uspto-grants-2010_12